The most recent info is of Feb 8 of this year - a few days ago.
Some history - in June 2004, the FDA determined Gepirone ER was not approvable. Fabre-Kramer Pharmaceuticals (a privately held specialty pharmceutical company) re-acquired all rights to it from Organon, assuming Organon would continue its responsibility for ongoing pediatric trials. At that time, if the FDA approved it in the future, Organon would receive a milestone payment & also receive royalties based on future sales.
Now...as of Feb 8 of this year...GSK & Fabre-Kramer announced an eclusive worldwide agreement which is expected to be submitted to the FDA for approval in this quarter. The agreement includes development & commercialisation as well as development opportunities for follow-up products (the "me-too's").
The terms of the agreement are confidential, but again, FKP will receive an upfront payment as well as milestone payments based on NDA approval & launch of the product.
Fabre-Kramer is based in Houston, TX & the contact there for US development is Tom Curry - 215-751-7002.
That's all I know - sorry - not too much!